Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Pani

Showing results (21-30 of 140) with videos related to

Pageof 14
Sort By:
European Journal of Pharmacology|November 8, 2005
Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptorsSimone Tambaro, Raymond Mongeau, Christian Dessi, et al.
International Journal of Technology Assessment in Health Care|December 10, 2015
MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITYSimona Montilla, Entela Xoxi, Pierluigi Russo, et al.
Clinical Drug Investigation|July 5, 2008
Practical issues with amisulpride in the management of patients with schizophreniaLuca Pani, José M Villagrán, Vassilis P Kontaxakis, et al.
Paediatric Anaesthesia|May 7, 2014
Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experienceIda Salvo, Giovanni Landoni, Marta Mucchetti, et al.
Behavioural Brain Research|July 10, 2012
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profileAndrea Mastinu, Marilena Pira, Luca Pani, et al.
Scientia Pharmaceutica|April 9, 2015
Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJJohn Joseph Borg, Andrea Laslop, Luca Pani, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 5, 2023
Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life studySimona Guerzoni, Flavia Lo Castro, Daria Brovia, et al.
Neuropsychobiology|August 5, 2004
Consensus on the use of substituted benzamides in psychiatric patientsGiorgio Racagni, Pier Luigi Canonico, Luigi Ravizza, et al.
European Journal of Pharmacology|August 12, 2009
Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in ratsGiorgio Marchese, Gianluca Casu, Paola Casti, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 10, 2011
Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trialsMaria Isaac, Spiros Vamvakas, Eric Abadie, et al.
Pageof 14

Showing results (21-30 of 140) with videos related to

Sort By:
Pageof 14
European Journal of Pharmacology|November 8, 2005
Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptorsSimone Tambaro, Raymond Mongeau, Christian Dessi, et al.
International Journal of Technology Assessment in Health Care|December 10, 2015
MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITYSimona Montilla, Entela Xoxi, Pierluigi Russo, et al.
Clinical Drug Investigation|July 5, 2008
Practical issues with amisulpride in the management of patients with schizophreniaLuca Pani, José M Villagrán, Vassilis P Kontaxakis, et al.
Paediatric Anaesthesia|May 7, 2014
Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experienceIda Salvo, Giovanni Landoni, Marta Mucchetti, et al.
Behavioural Brain Research|July 10, 2012
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profileAndrea Mastinu, Marilena Pira, Luca Pani, et al.
Scientia Pharmaceutica|April 9, 2015
Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJJohn Joseph Borg, Andrea Laslop, Luca Pani, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 5, 2023
Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life studySimona Guerzoni, Flavia Lo Castro, Daria Brovia, et al.
Neuropsychobiology|August 5, 2004
Consensus on the use of substituted benzamides in psychiatric patientsGiorgio Racagni, Pier Luigi Canonico, Luigi Ravizza, et al.
European Journal of Pharmacology|August 12, 2009
Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in ratsGiorgio Marchese, Gianluca Casu, Paola Casti, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 10, 2011
Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trialsMaria Isaac, Spiros Vamvakas, Eric Abadie, et al.
Pageof 14